Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor.

A77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, was administered to asymptomatic HIV-1-infected patients in a phase I trial. The drug was given by continuous intravenous infusion at dosages of 0.035, 0.07, 0.14, and 0.28 mg/kg of body weight per h. The drug was give...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Εκδόθηκε σε:	Antimicrob Agents Chemother
Κύριοι συγγραφείς:	Reedijk, M, Boucher, C A, van Bommel, T, Ho, D D, Tzeng, T B, Sereni, D, Veyssier, P, Jurriaans, S, Granneman, R, Hsu, A
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	American Society for Microbiology (ASM) 1995
Θέματα:	Research Article
Διαθέσιμο Online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162781/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/7492104/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.7.1559
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!